NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates
Collaboration and license agreement allows the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, to enhance its access to antibody drug conjugate technologies and to expand its oncology pipeline Sutro’s Xpress CF+™ platforms to be utilized to develop...
Sutro Biopharma to Collaborate with University of California, San Francisco (UCSF), a Recombinant Antibody Network (RAN) Member
Collaboration to Express Antibodies and Antigens based on Sutro’s Technology Platform XpressCF+™ SAN FRANCISCO, Sept. 9, 2014 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug...
Sutro Biopharma’s Xpress CF+™ Technology Nominated for Best Scientific Innovation by World ADC
On July 1, 2014, World ADC announced the nominees for the World ADC Awards, 2014. Sutro Biopharma's cell free expression system, Xpress CF+™, has made the shortlist for nominations in the Best Scientific Innovation category. The award ceremony took place October 26,...
EnWave Signs Commercial License with Sutro Biopharma for powderREV® Technology
Press release published by EnWave Corporation regarding the recent agreement with Sutro Biopharma, Inc. Read more
Sutro Biopharma to Present at 21st Annual Future Leaders in the Biotech Industry Conference
SAN FRANCISCO, Mar. 24, 2014 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it will present at the 21st Annual...
Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma
SAN FRANCISCO, Jan. 07, 2014 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration...
Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
SAN FRANCISCO, Dec. 11, 2013 - Sutro Biopharma today announced that the company has secured $26 million in a Series D financing. The additional financing will fund the expansion of Sutro’s proprietary immuno-oncology product pipeline. Sutro is developing a new...
World ADC Summit 2013 – Dual-Warhead Antibody Drug Conjugate
SAN FRANCISCO, Oct. 15, 2013 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, presented today the first data involving a dual-warhead antibody drug conjugate...
Producing Homogeneous ADCs with Combination Warheads
Hallam, Trevor, Producing Homogeneous ADCs with Combination Warheads Presented at the 4th World ADC Summit, San Francisco (PDF) Read More
Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter
Scientific American Guest Blog Antibody-Drug Conjugates and Cancer Treatment: Making "Smart Bombs" Smarter By: Trevor J. Hallam Read More